---
schema_version: "secwatch.filing_event.v1"
accession: "0001615219-25-000125"
form_type: "8-K"
ticker: "DCOY"
cik: "0001615219"
company_name: "Decoy Therapeutics Inc."
filed_at: "2025-09-09T23:59:59+00:00"
generated_at: "2026-05-17T07:18:29.022313+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Salarius regains Nasdaq bid price compliance; merger with Decoy ongoing

## Summary
- Regained compliance with Nasdaq's minimum bid price requirement on Sept. 4, 2025.
- Subject to one-year Mandatory Panel Monitor; delisting risk if bid price falls below $1.00 again.
- Must also comply with Nasdaq equity standard by Oct. 20, 2025; currently noncompliant.
- Planned merger with Decoy Therapeutics to combine into Decoy Therapeutics, led by Decoy's co-founders.
- Decoy aims to file IND for pan-coronavirus antiviral within 12 months and advance other pipeline programs.

## SEC filing metadata
- accession: 0001615219-25-000125
- form_type: 8-K
- ticker: DCOY
- cik: 0001615219
- company_name: Decoy Therapeutics Inc.
- filed_at: 2025-09-09T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1615219/000161521925000125/0001615219-25-000125-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1615219/000161521925000125/flks-20250904.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001615219-25-000125
- JSON: https://secwatch.observer/filing/0001615219-25-000125.json
- Plain text: https://secwatch.observer/filing/0001615219-25-000125.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.